• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, March 31, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Early study finds new lymphoma drug effective

Bioengineer by Bioengineer
May 13, 2022
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.

Lymphoma cells

Credit: National Cancer Institute/National Institutes of Health

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.

Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.

A much smaller proportion of the 33 participants with follicular lymphoma, a similar cancer, responded to the drug. But imaging showed no signs of cancer for 18% of those who did.

The most common side effects ranged from diarrhea, bruising and rashes to colds, fevers and reduced levels of white blood cells, which are part of the immune system and important for fighting infections.

Based on the results of this research  as well as a  secondary study named MAGNOLIA, the Food and Drug Administration approved zanubrutinib on a contingent basis for adults with marginal zone lymphoma that has returned or proven resistant to other treatments.

“Treatment options with improved tolerability and better disease control were much needed for marginal zone lymphoma and follicular lymphoma,” said Tycel Phillips, M.D., a hematologist at the Rogel Cancer Center, a clinical associate professor at the University of Michigan Medical School and the lead author of the study. “While the small size of this study limits broad conclusions, the safety and efficacy results highlight the potential for zanubrutinib as an addition to available therapies for these cancers.”

Lymphoma is a cancer that begins in the lymphatic system, the tissues and organs that produce and store white blood cells. Marginal zone and follicular lymphomas develop when white blood cells called B cells become damaged and start to grow uncontrollably.

Thus far, physicians have not been able to cure patients of their marginal zone or follicular lymphomas with chemotherapy, so researchers have been eager to find other, more tolerable and successful treatments for the diseases.

Zanubrutinib is a novel type of drug called a Bruton Tyrosine Kinase inhibitor, which blocks an enzyme known as BTK that plays a crucial role in a signaling pathway lymphomas are often dependent on in order to survive and grow. The medication is only the third BTK inhibitor to be approved for cancers that begin in B cells.



Journal

Blood Advances

DOI

10.1182/bloodadvances.2021006083

Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Article Title

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

Article Publication Date

7-Apr-2022

COI Statement

Tycel Phillips has been a paid consultant for BeiGene, Ltd., the manufacturer of the drug studied in this clinical trial.

Share12Tweet8Share2ShareShareShare2

Related Posts

Figure 7

Metformin & leucine prevent cellular senescence & proteostasis disruption

March 31, 2023
blood brain barrier

New study offers clues to how cancer spreads to the brain

March 31, 2023

Oregon State researchers develop new model for quickly evaluating potential cervical cancer drugs

March 31, 2023

Researchers report that the outcome of patients with a rare type of astrocytoma, a neuron tumor, is worse than expected

March 31, 2023

POPULAR NEWS

  • ChatPandaGPT

    Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

    68 shares
    Share 27 Tweet 17
  • Extinction of steam locomotives derails assumptions about biological evolution

    49 shares
    Share 20 Tweet 12
  • Northern and southern resident orcas hunt differently, which may help explain the decline of southern orcas

    44 shares
    Share 18 Tweet 11
  • Skipping breakfast may compromise the immune system

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cookin’ with gas: UWO professor earns patent for flameless industrial oven

After spinal cord injury, kinesthetic sense helps restore movement, model suggests

Plastic transistor amplifies biochemical sensing signal

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 48 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In